218 related articles for article (PubMed ID: 18663308)
21. Highly purified 1000-cSt silicone oil for treatment of human immunodeficiency virus-associated facial lipoatrophy: an open pilot trial.
Jones DH; Carruthers A; Orentreich D; Brody HJ; Lai MY; Azen S; Van Dyke GS
Dermatol Surg; 2004 Oct; 30(10):1279-86. PubMed ID: 15458523
[TBL] [Abstract][Full Text] [Related]
22. Assessment of quality of life in patients with primary axillary hyperhidrosis before and after suction-curettage.
Bechara FG; Gambichler T; Bader A; Sand M; Altmeyer P; Hoffmann K
J Am Acad Dermatol; 2007 Aug; 57(2):207-12. PubMed ID: 17368632
[TBL] [Abstract][Full Text] [Related]
23. Sustained efficacy and high patient satisfaction after cheek enhancement with a new hyaluronic acid dermal filler.
Kestemont P; Cartier H; Trevidic P; Rzany B; Sattler G; Kerrouche N; Dhuin JC
J Drugs Dermatol; 2012 Jan; 11(1 Suppl):s9-16. PubMed ID: 22497039
[TBL] [Abstract][Full Text] [Related]
24. Evaluation of Coleman lipostructure for treatment of facial lipoatrophy in patients with human immunodeficiency virus and parameters associated with the efficiency of this technique.
Burnouf M; Buffet M; Schwarzinger M; Roman P; Bui P; Prévot M; Deleuze J; Morini JP; Franck N; Gorin I; Dupin N
Arch Dermatol; 2005 Oct; 141(10):1220-4. PubMed ID: 16230558
[TBL] [Abstract][Full Text] [Related]
25. HIV-associated facial lipoatrophy treated with injectable silicone oil: a pilot study.
Chen F; Carruthers A; Humphrey S; Carruthers J
J Am Acad Dermatol; 2013 Sep; 69(3):431-7. PubMed ID: 23711767
[TBL] [Abstract][Full Text] [Related]
26. Restorative interventions for HIV facial lipoatrophy.
Carey D; Liew S; Emery S
AIDS Rev; 2008; 10(2):116-24. PubMed ID: 18615122
[TBL] [Abstract][Full Text] [Related]
27. HIV-associated facial lipoatrophy--review of current therapy options.
Bechara FG; Sand M; Potthoff A; Altmeyer P; Brockmeyer NH;
Eur J Med Res; 2008 Mar; 13(3):93-9. PubMed ID: 18499554
[TBL] [Abstract][Full Text] [Related]
28. Comparison between lipofilling and a nonabsorbable filler for facial wasting rehabilitation in HIV-positive patients.
Rauso R; Curinga G; Santillo V; Corvo G; Tartaro G
J Craniofac Surg; 2011 Sep; 22(5):1684-8. PubMed ID: 21959413
[TBL] [Abstract][Full Text] [Related]
29. Use of hyaluronic acid for soft tissue augmentation of HIV-associated facial lipodystrophy.
Gooderham M; Solish N
Dermatol Surg; 2005 Jan; 31(1):104-8. PubMed ID: 15720106
[TBL] [Abstract][Full Text] [Related]
30. [Treatment of HIV facial lipoatrophy with a submalar porous polyethylene implant (Medpor)].
Claude O; Domergue Than Trong E; Blanc R; Ascher B; Bagot M; Meningaud JP; Lantieri L
Ann Chir Plast Esthet; 2009 Feb; 54(1):21-8. PubMed ID: 19042066
[TBL] [Abstract][Full Text] [Related]
31. The impact of facial lipoatrophy treatment with polymethyl methacrylate in AIDS patients as measured by four quality-of-life questionnaires.
Warde M; Gragnani A; Gomes H; Hochman B; Ferreira LM
Int J STD AIDS; 2011 Oct; 22(10):596-9. PubMed ID: 21998182
[TBL] [Abstract][Full Text] [Related]
32. Use of polylactic acid implants to correct facial lipoatrophy in human immunodeficiency virus 1-positive individuals receiving combination antiretroviral therapy.
Cattelan AM; Bauer U; Trevenzoli M; Sasset L; Campostrini S; Facchin C; Pagiaro E; Gerzeli S; Cadrobbi P; Chiarelli A
Arch Dermatol; 2006 Mar; 142(3):329-34. PubMed ID: 16549708
[TBL] [Abstract][Full Text] [Related]
33. Local treatment of facial lipodystrophy in patients receiving HIV protease inhibitor therapy.
Ritt MJ; Hillebrand-Haverkort ME; ten Veen JH
Acta Chir Plast; 2001; 43(2):54-6. PubMed ID: 11505710
[TBL] [Abstract][Full Text] [Related]
34. Longevity of effects of hyaluronic acid plus lidocaine facial filler.
Raspaldo H; De Boulle K; Levy PM
J Cosmet Dermatol; 2010 Mar; 9(1):11-5. PubMed ID: 20367667
[TBL] [Abstract][Full Text] [Related]
35. Calcium hydroxylapatite versus nonanimal stabilized hyaluronic acid for the correction of nasolabial folds: a 12-month, multicenter, prospective, randomized, controlled, split-face trial.
Moers-Carpi MM; Tufet JO
Dermatol Surg; 2008 Feb; 34(2):210-5. PubMed ID: 18093199
[TBL] [Abstract][Full Text] [Related]
36. Preliminary experiences with Bio-Alcamid in HIV facial lipoatrophy.
Ramon Y; Fodor L; Ullmann Y
Dermatology; 2007; 214(2):151-4. PubMed ID: 17341865
[TBL] [Abstract][Full Text] [Related]
37. A multicenter, randomized trial comparing calcium hydroxylapatite to two hyaluronic acids for treatment of nasolabial folds.
Moers-Carpi M; Vogt S; Santos BM; Planas J; Vallve SR; Howell DJ
Dermatol Surg; 2007 Dec; 33 Suppl 2():S144-51. PubMed ID: 18086052
[TBL] [Abstract][Full Text] [Related]
38. Polyacrylamide gel injection for treatment of human immunodeficiency virus-associated facial lipoatrophy: 18 months follow-up.
Rauso R; Freda N; Parlato V; Gherardini G; Amore R; Tartaro G
Dermatol Surg; 2011 Nov; 37(11):1584-9. PubMed ID: 21806709
[TBL] [Abstract][Full Text] [Related]
39. Contemporary surgical management of HIV-associated facial lipoatrophy.
Funk E; Bressler FJ; Brissett AE
Otolaryngol Head Neck Surg; 2006 Jun; 134(6):1015-22. PubMed ID: 16730549
[TBL] [Abstract][Full Text] [Related]
40. Safety of nonanimal stabilized hyaluronic acid dermal fillers in patients with skin of color: a randomized, evaluator-blinded comparative trial.
Taylor SC; Burgess CM; Callender VD
Dermatol Surg; 2009 Oct; 35 Suppl 2():1653-60. PubMed ID: 19807760
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
